39
New Articles
Find Your Next Job !
Another industry that isn’t currently in the plant-touching realm that will be directly impacted by medical marijuana being rescheduled to Schedule III is the healthcare industry. This piece takes us to the story unfolding in exam rooms and hospital corridors across the country. Now that state-authorized medical marijuana has formally moved to Schedule III, physicians, pharmacists, hospitals, and healthcare systems are navigating new territory.
Clinicians, compliance officers, and healthcare administrators likely have many questions about their policy manuals, prescribing protocols, and compliance obligations and are generally wondering what changed this past week and what they need to do about it. Let’s walk through it.
For decades, Schedule I status loomed over every physician-patient conversation about medical marijuana like a legal storm cloud. Certified physicians in states with legalized medical marijuana could recommend marijuana — the Ninth Circuit held in Conant v. Walters that the First Amendment protected that speech — but they could not prescribe it. That distinction mattered enormously, and the practical effect was that physicians often soft-pedaled the conversation entirely, fearful of DEA scrutiny and hospital credentialing consequences.
Schedule III changes the calculus. With state-licensed medical marijuana now carrying the same federal scheduling status as anabolic steroids and ketamine, the legal framework around physician engagement with marijuana has fundamentally shifted. Physicians can — and frankly should — begin revisiting how they discuss medical marijuana with qualifying patients.
That said, “easier” does not mean “uncomplicated.” Schedule III substances can be prescribed, but they are still controlled substances. The Controlled Substances Act still applies in full: DEA registration, prescription monitoring programs, and record-keeping requirements — many of the same conditions already existing in state medical marijuana programs. Physicians who prescribe Schedule III substances are already familiar with this world. But they have not, until now, had marijuana in it.
Most institutional marijuana policies were written in a Schedule I world – perhaps with some state law elements in states with medical marijuana programs. But most of those policies do not contemplate a Schedule III reality.
Previously, hospitals had good reasons to prohibit on-premises marijuana use, decline to incorporate it into formularies, and instruct physicians not to recommend it to patients. Some of those reasons were about federal law. Some were about accreditation. Some were about simple institutional risk aversion.
Recently, several states passed laws requiring patient access to medical marijuana in certain situations, including California, Virginia, Colorado, and Washington. These policies were likely already in the process of being revised prior to April 22, but rescheduling accelerates that revision process considerably.
Now, at least the federal law rationale is eroding. Medical marijuana, under state license, is no longer in the same scheduling category as heroin. For health systems that have been waiting on that specific hook to re-evaluate their policies, the hook is gone. And that means policy review is not just advisable — it is probably overdue.
Specifically, healthcare facilities should be asking:
None of these questions have easy answers yet. But the institutions that are asking them now will be better positioned than those waiting for a compliance crisis to force the conversation.
Perhaps no healthcare professional has been more thoroughly sidelined by Schedule I status than the pharmacist. Federal law flatly prohibits pharmacies — including hospital pharmacies — from dispensing Schedule I substances. That prohibition is one reason the state-licensed dispensary model developed in the first place: Someone had to fill the patient access gap that pharmacies could not.
Schedule III status opens a door that has been bolted shut since 1970. Pharmacists can, and routinely do, dispense Schedule III controlled substances. Whether and how they will be permitted to dispense state-licensed medical marijuana products are questions that will require DEA rulemaking, FDA approval of certain products, state pharmacy board guidance and, in some cases, legislative action. But the legal architecture no longer categorically excludes them.
For patient access, this matters enormously. Dispensaries have served a critical function, and they are not going anywhere. But the integration of medical cannabis into the mainstream pharmacy system — particularly for patients in rural areas, those with mobility limitations, or those who rely on insurance-based prescription benefits — could meaningfully expand access in ways the dispensary model alone never could.
Do not expect this to happen overnight. The regulatory pathway from “Schedule III” to “available at your local pharmacy” is long and winding. But the destination is now at least theoretically reachable, which was not true until over a week ago.
Insurance coverage for medical marijuana has been, to put it charitably, a mess. Insurers — private and public alike — have consistently declined to cover marijuana on the grounds that it is a Schedule I substance with no accepted medical use. Medicaid and Medicare have been similarly positioned, until the newly rolled out Substance Access Beneficiary Engagement Incentive program for a limited amount of “hemp” products.
Schedule III upends at least part of that rationale. The final order, by its own terms, reflects a federal acknowledgment that state-licensed medical marijuana has accepted medical uses and a more favorable safety profile than Schedule I substances. That is significant for the insurance coverage conversation, even if the coverage itself does not automatically follow.
Schedule III status, however, does not mandate insurance coverage. It removes one barrier, but it does not create a replacement requirement. Coverage decisions by private insurers involve actuarial analysis, formulary politics and, in some cases, state insurance regulations, none of which the rescheduling order and rule alter. And Medicare and Medicaid coverage for cannabis products would require separate federal action.
Still, the conversation has at least shifted. Patients and their advocates now have a stronger argument than they did last month. Healthcare systems negotiating formulary arrangements with payors have more ground to stand on. And insurers who have been quietly watching the rescheduling saga will need to start giving their medical marijuana coverage posture a hard look.
Patient access is not just about dispensaries and insurance cards. It is also about the clinical evidence base that informs what physicians recommend and what payors cover. On that front, Schedule III status carries real significance.
Schedule I research restrictions have been a consistent drag on the evidence base for medical marijuana. Researchers seeking to study Schedule I substances face a labyrinthine approval process through DEA registration, NIDA supply controls and, in some contexts, FDA review — a process notorious for delays, limited supply chains, and institutional risk aversion. Much of the clinical literature on marijuana has therefore been generated outside the United States, a situation that U.S. regulators have simultaneously complained about and perpetuated.
Schedule III research requirements are meaningfully less burdensome. While investigators will still need DEA registration and appropriate institutional protocols, the ceiling of Schedule I restrictions will be lifted. That should accelerate clinical trials, expand the investigator pool, and — over time — generate the kinds of evidence that inform everything from physician practice to insurance coverage to FDA approval decisions. This is a medium-term benefit, not an overnight fix. But it is a genuine one.
For the cannabis industry broadly, rescheduling is a financial story — 280E relief, expected banking improvements, and the prospect of expanded access to capital markets. For the healthcare sector, the story involves professional norms, institutional policies, patient conversations, and a long-overdue integration of a widely used therapeutic into the mainstream medical system.
Physicians, pharmacists, hospital administrators, and compliance officers should not assume that the status quo holds simply because the changes are complex and the guidance is incomplete. The ground has shifted. The work of figuring out what to do about it starts now.
There’s more to come as guidance from DEA, the pharmacy boards, and federal health agencies begins to fill in the gaps.
More Upcoming Events
Sign Up for any (or all) of our 25+ Newsletters
You are responsible for reading, understanding, and agreeing to the National Law Review’s (NLR’s) and the National Law Forum LLC’s Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free-to-use, no-log-in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only. Any legal analysis, legislative updates, or other content and links should not be construed as legal or professional advice or a substitute for such advice. No attorney-client or confidential relationship is formed by the transmission of information between you and the National Law Review website or any of the law firms, attorneys, or other professionals or organizations who include content on the National Law Review website. If you require legal or professional advice, kindly contact an attorney or other suitable professional advisor.
Some states have laws and ethical rules regarding solicitation and advertisement practices by attorneys and/or other professionals. The National Law Review is not a law firm nor is www.NatLawReview.com intended to be a referral service for attorneys and/or other professionals. The NLR does not wish, nor does it intend, to solicit the business of anyone or to refer anyone to an attorney or other professional. NLR does not answer legal questions nor will we refer you to an attorney or other professional if you request such information from us.
Under certain state laws, the following statements may be required on this website and we have included them in order to be in full compliance with these rules. The choice of a lawyer or other professional is an important decision and should not be based solely upon advertisements. Attorney Advertising Notice: Prior results do not guarantee a similar outcome. Statement in compliance with Texas Rules of Professional Conduct. Unless otherwise noted, attorneys are not certified by the Texas Board of Legal Specialization, nor can NLR attest to the accuracy of any notation of Legal Specialization or other Professional Credentials.
The National Law Review – National Law Forum LLC 2070 Green Bay Rd., Suite 178, Highland Park, IL 60035 Telephone (708) 357-3317 or toll-free (877) 357-3317. If you would like to contact us via email please click here.
Copyright ©2026 National Law Forum, LLC
Find Your Next Job !
Another industry that isn’t currently in the plant-touching realm that will be directly impacted by medical marijuana being rescheduled to Schedule III is the healthcare industry. This piece takes us to the story unfolding in exam rooms and hospital corridors across the country. Now that state-authorized medical marijuana has formally moved to Schedule III, physicians, pharmacists, hospitals, and healthcare systems are navigating new territory.
Clinicians, compliance officers, and healthcare administrators likely have many questions about their policy manuals, prescribing protocols, and compliance obligations and are generally wondering what changed this past week and what they need to do about it. Let’s walk through it.
For decades, Schedule I status loomed over every physician-patient conversation about medical marijuana like a legal storm cloud. Certified physicians in states with legalized medical marijuana could recommend marijuana — the Ninth Circuit held in Conant v. Walters that the First Amendment protected that speech — but they could not prescribe it. That distinction mattered enormously, and the practical effect was that physicians often soft-pedaled the conversation entirely, fearful of DEA scrutiny and hospital credentialing consequences.
Schedule III changes the calculus. With state-licensed medical marijuana now carrying the same federal scheduling status as anabolic steroids and ketamine, the legal framework around physician engagement with marijuana has fundamentally shifted. Physicians can — and frankly should — begin revisiting how they discuss medical marijuana with qualifying patients.
That said, “easier” does not mean “uncomplicated.” Schedule III substances can be prescribed, but they are still controlled substances. The Controlled Substances Act still applies in full: DEA registration, prescription monitoring programs, and record-keeping requirements — many of the same conditions already existing in state medical marijuana programs. Physicians who prescribe Schedule III substances are already familiar with this world. But they have not, until now, had marijuana in it.
Most institutional marijuana policies were written in a Schedule I world – perhaps with some state law elements in states with medical marijuana programs. But most of those policies do not contemplate a Schedule III reality.
Previously, hospitals had good reasons to prohibit on-premises marijuana use, decline to incorporate it into formularies, and instruct physicians not to recommend it to patients. Some of those reasons were about federal law. Some were about accreditation. Some were about simple institutional risk aversion.
Recently, several states passed laws requiring patient access to medical marijuana in certain situations, including California, Virginia, Colorado, and Washington. These policies were likely already in the process of being revised prior to April 22, but rescheduling accelerates that revision process considerably.
Now, at least the federal law rationale is eroding. Medical marijuana, under state license, is no longer in the same scheduling category as heroin. For health systems that have been waiting on that specific hook to re-evaluate their policies, the hook is gone. And that means policy review is not just advisable — it is probably overdue.
Specifically, healthcare facilities should be asking:
None of these questions have easy answers yet. But the institutions that are asking them now will be better positioned than those waiting for a compliance crisis to force the conversation.
Perhaps no healthcare professional has been more thoroughly sidelined by Schedule I status than the pharmacist. Federal law flatly prohibits pharmacies — including hospital pharmacies — from dispensing Schedule I substances. That prohibition is one reason the state-licensed dispensary model developed in the first place: Someone had to fill the patient access gap that pharmacies could not.
Schedule III status opens a door that has been bolted shut since 1970. Pharmacists can, and routinely do, dispense Schedule III controlled substances. Whether and how they will be permitted to dispense state-licensed medical marijuana products are questions that will require DEA rulemaking, FDA approval of certain products, state pharmacy board guidance and, in some cases, legislative action. But the legal architecture no longer categorically excludes them.
For patient access, this matters enormously. Dispensaries have served a critical function, and they are not going anywhere. But the integration of medical cannabis into the mainstream pharmacy system — particularly for patients in rural areas, those with mobility limitations, or those who rely on insurance-based prescription benefits — could meaningfully expand access in ways the dispensary model alone never could.
Do not expect this to happen overnight. The regulatory pathway from “Schedule III” to “available at your local pharmacy” is long and winding. But the destination is now at least theoretically reachable, which was not true until over a week ago.
Insurance coverage for medical marijuana has been, to put it charitably, a mess. Insurers — private and public alike — have consistently declined to cover marijuana on the grounds that it is a Schedule I substance with no accepted medical use. Medicaid and Medicare have been similarly positioned, until the newly rolled out Substance Access Beneficiary Engagement Incentive program for a limited amount of “hemp” products.
Schedule III upends at least part of that rationale. The final order, by its own terms, reflects a federal acknowledgment that state-licensed medical marijuana has accepted medical uses and a more favorable safety profile than Schedule I substances. That is significant for the insurance coverage conversation, even if the coverage itself does not automatically follow.
Schedule III status, however, does not mandate insurance coverage. It removes one barrier, but it does not create a replacement requirement. Coverage decisions by private insurers involve actuarial analysis, formulary politics and, in some cases, state insurance regulations, none of which the rescheduling order and rule alter. And Medicare and Medicaid coverage for cannabis products would require separate federal action.
Still, the conversation has at least shifted. Patients and their advocates now have a stronger argument than they did last month. Healthcare systems negotiating formulary arrangements with payors have more ground to stand on. And insurers who have been quietly watching the rescheduling saga will need to start giving their medical marijuana coverage posture a hard look.
Patient access is not just about dispensaries and insurance cards. It is also about the clinical evidence base that informs what physicians recommend and what payors cover. On that front, Schedule III status carries real significance.
Schedule I research restrictions have been a consistent drag on the evidence base for medical marijuana. Researchers seeking to study Schedule I substances face a labyrinthine approval process through DEA registration, NIDA supply controls and, in some contexts, FDA review — a process notorious for delays, limited supply chains, and institutional risk aversion. Much of the clinical literature on marijuana has therefore been generated outside the United States, a situation that U.S. regulators have simultaneously complained about and perpetuated.
Schedule III research requirements are meaningfully less burdensome. While investigators will still need DEA registration and appropriate institutional protocols, the ceiling of Schedule I restrictions will be lifted. That should accelerate clinical trials, expand the investigator pool, and — over time — generate the kinds of evidence that inform everything from physician practice to insurance coverage to FDA approval decisions. This is a medium-term benefit, not an overnight fix. But it is a genuine one.
For the cannabis industry broadly, rescheduling is a financial story — 280E relief, expected banking improvements, and the prospect of expanded access to capital markets. For the healthcare sector, the story involves professional norms, institutional policies, patient conversations, and a long-overdue integration of a widely used therapeutic into the mainstream medical system.
Physicians, pharmacists, hospital administrators, and compliance officers should not assume that the status quo holds simply because the changes are complex and the guidance is incomplete. The ground has shifted. The work of figuring out what to do about it starts now.
There’s more to come as guidance from DEA, the pharmacy boards, and federal health agencies begins to fill in the gaps.
More Upcoming Events
Sign Up for any (or all) of our 25+ Newsletters
You are responsible for reading, understanding, and agreeing to the National Law Review’s (NLR’s) and the National Law Forum LLC’s Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free-to-use, no-log-in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only. Any legal analysis, legislative updates, or other content and links should not be construed as legal or professional advice or a substitute for such advice. No attorney-client or confidential relationship is formed by the transmission of information between you and the National Law Review website or any of the law firms, attorneys, or other professionals or organizations who include content on the National Law Review website. If you require legal or professional advice, kindly contact an attorney or other suitable professional advisor.
Some states have laws and ethical rules regarding solicitation and advertisement practices by attorneys and/or other professionals. The National Law Review is not a law firm nor is www.NatLawReview.com intended to be a referral service for attorneys and/or other professionals. The NLR does not wish, nor does it intend, to solicit the business of anyone or to refer anyone to an attorney or other professional. NLR does not answer legal questions nor will we refer you to an attorney or other professional if you request such information from us.
Under certain state laws, the following statements may be required on this website and we have included them in order to be in full compliance with these rules. The choice of a lawyer or other professional is an important decision and should not be based solely upon advertisements. Attorney Advertising Notice: Prior results do not guarantee a similar outcome. Statement in compliance with Texas Rules of Professional Conduct. Unless otherwise noted, attorneys are not certified by the Texas Board of Legal Specialization, nor can NLR attest to the accuracy of any notation of Legal Specialization or other Professional Credentials.
The National Law Review – National Law Forum LLC 2070 Green Bay Rd., Suite 178, Highland Park, IL 60035 Telephone (708) 357-3317 or toll-free (877) 357-3317. If you would like to contact us via email please click here.
Copyright ©2026 National Law Forum, LLC